


PHARMACEUTICAL 2020

Mirum Pharmaceuticals Inc. Rank 132 of 362







PHARMACEUTICAL 2020

Mirum Pharmaceuticals Inc. Rank 132 of 362



The relative strengths and weaknesses of Mirum Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Mirum Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 176% points. The greatest weakness of Mirum Pharmaceuticals Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 94% points.

The company's Economic Capital Ratio, given in the ranking table, is -86%, being 217% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	119,363
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	13,076
Liabilities, Non-Current	3,287
Other Assets	25,977
Other Compr. Net Income	129
Other Expenses	21
Other Liabilities	0
Other Net Income	2,211
Property and Equipment	1,372
Research and Development	42,991
Revenues	0
Selling, General and Administrative Expense	11,752

Output Variable	Value in 1000 USD
Assets	146,712
Liabilities	16,363
Expenses	54,764
Stockholders Equity	130,349
Net Income	-52,553
Comprehensive Net Income	-52,488
Economic Capital Ratio	-86%